Evidence suggests that subgingival periodontal treatment, together with systemic antibiotics, in patients with metabolic syndrome and periodontal disease, could improve the systemic inflammation present in these patients, which would be evidenced by a reduction in markers such as C-reactive protein (CRP), interleukins, and TNF-α (5, 6). This evidence concerns the gene CRP and metabolic syndrome.